Stakeholder Insight: Parkinson's Disease - Evidence of Neuroprotection Essential to Progress Treatment Dynamics

Tuesday February 5, 1:57 pm ET
http://biz.yahoo.com/bw/080205/20080205005673.html?.v=1

DUBLIN, Ireland--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/reports/c81848) has announced the addition of Stakeholder Insight: Parkinson's Disease - Evidence of neuroprotection essential to progress treatment dynamics to their offering.

Parkinson's disease (PD) is a progressive, degenerative condition of the central nervous system that affects the way the brain coordinates body movements, including walking, talking and writing. PD affects less than 1% of the population in the seven major markets (7MM); with patients typically being diagnosed in their early sixties and living for over 18 years after the onset of first symptoms.

Scope

- Overview of epidemiology, presentation, and diagnostic assessment in PD

- Breakdown of first-line treatment regimens for early-, mid-, and advanced-stage disease, with analysis of second-line add-on and switching dynamics

- Influences on neurologists treatment decisions and their perception of current brands

- Evaluation of treatment outcomes and surgical procedures for PD

Highlights of this title

Neurologists indicated that the DAs Mirapex (pramipexole) and Requip (ropinirole) are generally the initial treatment of choice for younger presenting patients. While levodopa is reserved for patients over 65 years of age, neurologists may prescribe the MAOIs selegiline and rasagiline (Azilect) in young patients with only mild symptoms at onset.

Neurologists indicated that only 36% of advanced-stage PD patients are adequately controlled by pharmacological therapy. Considering the even distribution of patient severities (30% early-stage, 39% mid-stage and 31% advanced-stage), the advanced-stage patient group is particularly poorly served by current therapies.

Neurologists estimated that approximately 9% of all PD patients will eventually require surgery. Deep Brain Stimulation is by far the most common surgical procedure used in the 7MM and neurologists indicated that over 70% of patients receiving it experience both a reduction in PD symptoms and a reduction in the dose of pharmacological medication.

Key reasons to purchase this title

- Target prescribers more effectively, through an understanding of prescribing behavior and its influences

- Validate new product forecasting based on diagnosis and treatment rates, and the likely rate of uptake for new products

- Benchmark brand awareness and perceptions surrounding product positioning in order to formulate competitive lifecycle management strategies

Content Outline:

About Us Healthcare

Chapter 1 Executive Summary

Chapter 2 Introduction And Scope

Chapter 3 Country Treatment Trees

Chapter 4 Epidemiology And Patient Segmentation

Chapter 5 Presentation, Diagnosis And Comorbidities

Chapter 6 Treatment Options And Guidelines

Chapter 7 Prescribing Trends In Parkinsons Disease

Chapter 8 Prescribing Influences And Brand Assessment

Chapter 9 Treatments Outcomes And Surgery

Bibliography

Appendix A

Appendix B

List of Tables

List of Figures

Companies Mentioned:

- AM nv

- Boehringer Ingelheim GmbH

- Bristol-Myers Squibb Company

- Britannia Building Society

- Cytokine PharmaSciences, Inc

- Danka Business Systems PLC

- Electronic Data Systems Corporation

- Eli Lilly and Company

- GlaxoSmithKline Plc

- Gottschalks Inc

- H.J. Heinz Company

- Hughes Communications Inc

- IMS Health

- Insight Communications Company, Inc.

- Medtronic, Inc.

- Merck & Co., Inc.

- NICE Systems Ltd

- Novartis AG

- Pepper Construction Group, LLC

- Pfizer Inc

- Safety Insurance Group, Inc.

- Schwarz Pharma AG

- Solvay Group

- Taylor Corporation

- Vernalis Group PLC

For more information visit http://www.researchandmarkets.com/reports/c81848

Source: Datamonitor


Contact:

Research and Markets
Laura Wood, Senior Manager
Fax: +353 1 4100 980
press@researchandmarkets.com

they want 16000, yes,, sixteen thou for that report!! euros!